GlobeNewswire PharmaOriginal article
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
IRX-101Positive
AI Analysis
Summary
Tarsus Pharmaceuticals acquires iRenix Medical and its late-stage asset IRX-101, which targets vision loss in millions of patients with potential to improve standard of care in eye care.
Importance:6/10
Sentiment:
0.60
acquisitioneye carelate-stage assetstrategy expansion
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 8, 2026 8:05 PM